Qsymia, a combination of phentermine and topiramate, has been approved by the FDA for chronic weight management.
- TRADE NAMES: Qsymia (Vivus); Qudexy (Upsher-Smith); Topamax (Janssen); Trokendi XR (Supernus)
- INDICATIONS: Partial onset seizures; migraine
- CLASS: Anti-obesity / weight loss pharmacotherapy, Anticonvulsant (see also antiepileptic (anti-seizure)), Mood stabilizer, Neuroprotectant
- HALF-LIFE: 21 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Eslicarbazepine, Levonorgestrel, Metformin, Rufinamide, Ulipristal, Valproic Acid
- See adverse reactions attributed to class:
Anti-obesity / weight loss pharmacotherapy
Please login to view the rest of this drug profile.
Page last updated 01/30/2025
